亚司匹林162毫克与81毫克用于高风险肥胖个体的妊娠前预防:一个比较有效性的开放标签随机试验 (ASPREO)
Farah H Amro1, Sean C Blackwell1, Claudia Pedroza2
1Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, The University of Texas Health, Science Center at Houston, Houston, TX.
American journal of obstetrics and gynecology
|July 8, 2024
概括
较高剂量的阿司匹林 (162毫克) 与标准的81毫克剂量相比,在肥胖的高危孕妇中,降低严重子宫前的概率为78%. 建议对这一重要发现进行进一步的研究.
科学领域:
- 产科和妇科 产科和妇科
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前的指导方针建议每天服用81毫克阿司匹林,用于预防高危孕妇的孕前.
- 在某些地区使用更高的剂量 (高达150毫克),并且由于剂量或阿司匹林耐药性,肥胖人口的疗效可能会降低.
研究的目的:
- 评估每天162毫克的阿司匹林是否比81毫克更有效地预防高风险,肥胖的孕妇患有严重特征的妊娠前兆.
主要方法:
- 一项随机试验于2019年5月至2022年11月进行.
- 参与者 (BMI ≥30 kg/m2,高风险因素) 每天服用162毫克或81毫克阿司匹林,直到分娩.
- 主要结局是患有严重特征的孕前;使用贝叶斯分析.
主要成果:
- 该研究随机选择了220名参与者;209人拥有主要结果数据.
- 35% (162毫克组) 与40% (81毫克组) 发生了具有严重特征的孕前,后相对风险为0.88.
- 贝叶斯分析显示,162毫克剂量的效益概率为78%,估计减少了12%.
结论:
- 在高风险的肥胖孕妇中,162毫克阿司匹林有78%的概率减少严重的孕前,而81毫克相比.
- 这些发现支持需要进行更大规模的多中心试验来确认疗效.
- 二次结果和不良影响在各组之间是相似的.
相关概念视频
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430
01:16Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
01:21Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
395
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
395
01:26Peptic Ulcer Disease IV: Management
85
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
85